AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Neurogenic locus notch homolog protein 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries for receptors.

 Fig. 1. The sreening workflow of Receptor.AI

It includes extensive molecular simulations of the receptor in its native membrane environment and the ensemble virtual screening accounting for its conformational mobility. In the case of dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets are determined on and between the subunits to cover the whole spectrum of possible mechanisms of action.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P46531

UPID:

NOTC1_HUMAN

Alternative names:

Translocation-associated notch protein TAN-1

Alternative UPACC:

P46531; Q59ED8; Q5SXM3

Background:

Neurogenic locus notch homolog protein 1, also known as Translocation-associated notch protein TAN-1, plays a pivotal role in cell-fate determination, differentiation, proliferation, and apoptosis. It functions as a receptor for membrane-bound ligands such as Jagged-1, Jagged-2, and Delta-1, activating genes critical for development and tissue homeostasis. Notably, it is involved in angiogenesis, thymus maturation of CD4(+) and CD8(+) cells, and cerebellar development.

Therapeutic significance:

Given its involvement in aortic valve disease 1 and Adams-Oliver syndrome 5, understanding the role of Neurogenic locus notch homolog protein 1 could open doors to potential therapeutic strategies. Its critical function in various developmental processes and disease states highlights its potential as a target for therapeutic intervention.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.